# A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment

> **NCT01548287** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 164 (actual)

## Conditions studied

- Mild Cognitive Impairment
- Mild Alzheimer's Disease

## Interventions

- **DRUG:** AZD5213
- **DRUG:** AZD5213
- **DRUG:** AZD5213
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01548287
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 164 (ACTUAL)
- **Last updated:** 2017-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01548287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01548287, "A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01548287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*